

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A pharmaceutical composition for the treatment of an ear disorder in a form selected from foam and mousse comprising:

- a. at least one pharmaceutical agent known to affect an ear disorder;
- b. a pharmaceutically acceptable carrier comprising at least one dispersing agent that is a foam forming agent;
- c. a dispensing device adapted for the dispensing the agent of a) admixed with the agent of b) to the external auditory meatus in a form selected from a foam and a mousse.

2. (Original) The pharmaceutical composition according to claim 1 wherein the dispersing agent is selected from a surfactant, a cholesteryl ester, a fatty acid, a phospholipid, a carbohydrate and a protein.

3. (Original) The pharmaceutical composition according to claim 2 wherein the surfactant is selected from a natural ionic surfactant, a synthetic ionic surfactant, a natural non-ionic surfactant, a synthetic non- ionic surfactant and a mixture thereof.

4. (Original) The pharmaceutical composition according to claim 1 wherein the dispensing device is selected from an aerosol and a non-aerosol dispensing device.

5. (Original) The pharmaceutical composition according to claim 4 wherein the dispensing device is an aerosol dispensing device, further comprising an aerosol propellant.

6. (Original) The pharmaceutical composition according to claim 1 wherein said dispensing device is a metered dose dispensing device.

7. (Original) The pharmaceutical composition according to claim 1 wherein the ear disorder is a condition that requires administration of a pharmaceutical composition

into the external auditory meatus of the treated subject, so as to thereby treat the subject.

8. (Original) The pharmaceutical composition according to claim 1, wherein the ear disorder is selected from an external ear disorder, a middle ear disorder and an inner ear disorder.

9. (Original) The pharmaceutical composition according to claim 8 wherein the external ear disorder is selected from otitis externa, necrotizing external otitis, otomycosis, perichondritis, bullous myringitis, herpes zoster oticus, contact dermatitis, ear eczema, lacerations of the external canal, presence of foreign bodies, pilar (sebaceous) cysts, epidermal cysts, benign lesions including exostosis and malignant lesions including basal cell epithelioma and squamous cell carcinoma.

10. (Original) The pharmaceutical composition of claim 9 wherein the external ear disorder is selected from otitis externa, and acute otitis externa.

11. (Original) The pharmaceutical composition according to claim 8 wherein the middle ear disorder is selected from otitis media, chronic otitis media, serous otitis media, acute and chronic suppurative otitis media, acute and chronic mastoiditis, adenoid hypertrophy, intratubal obstruction, middle ear obstruction, perforation of the tympanic membrane, cholesteatoma, tympanosclerosis, temporal bone fractures, barotrauma, glomus tumors and malignant neoplasia.

12. (Original) The pharmaceutical composition according to claim 11 the ear disorder is a middle ear disorder selected from acute otitis media, suppurative otitis media and mastoiditis.

13. (Original) The pharmaceutical composition of claim 1, wherein the ear disorder is otalgia induced by any physical or biological cause.

14. (Original) The pharmaceutical composition of claim 13, wherein the cause of the otalgia is selected from an allergic reaction, acute sinusitis, chronic sinusitis, a tooth

abscess, a sore throat with referred pain to the ear and otitis media.

15. (Original) The pharmaceutical composition according to claim 1 wherein the least one pharmaceutically active agent is selected from an antibiotic agent, an antibacterial agent, an antifungal agent, a steroid agent, an anti-inflammatory agent, a local anesthetic agent and a mixture thereof, in a therapeutically effective amount.

Claims 16-23 (Cancelled).

24. (Original) A method of preparing a pharmaceutical composition for the treatment of an ear disorder in the form selected from a foam and mousse, the method comprising the steps of:

- a. providing a pharmaceutical agent known to affect an ear disorder;
- b. admixing the pharmaceutical agent of step (a) with a suitable pharmaceutically acceptable carrier comprising a dispersing agent that is a foam forming agent;

c. introducing the mixture of (b) into a dispensing device adapted for the dispensing the composition to the external auditory meatus in the form of a foam or mousse.

Claims 25-28 (Cancelled).

29. (Original) The method according to claim 24 wherein said dispensing device is a metered dose dispensing device.

Claims 30-39 (Cancelled).

40. (Original) A method for the treatment of an ear disorder in a subject in need of such treatment, the method comprising the steps of:

- a. providing a pharmaceutical agent known to affect an ear disorder;
- b. admixing the pharmaceutical agent of step (a) together with a pharmaceutically acceptable carrier comprising a dispersing agent that is a foam forming agent;
- c. introducing the mixture formulation of step (b) in a container that enables the dispersion of said mixture in a form selected from foam and mousse; and

d. administering the formulation of step (c) to the external auditory meatus of said subject so as to thereby treat the ear disorder.

Claims 41-42 (Cancelled).

43. (Original) The method according to claim 40 wherein the dispensing device is selected from an aerosol dispensing device and a non-aerosol dispensing device.

Claim 44 (Cancelled).

45. (Original) The method according to claim 40 wherein said dispensing device is a metered dose dispensing device.

Claims 46-53 (Cancelled).

54. (Original) The method according to claim 40 wherein the least one pharmaceutically active agent is selected from an antibiotic agent, an antibacterial agent, an antifungal agent, a steroid agent, an anti-inflammatory agent,

a local anesthetic agent and a mixture thereof, in a therapeutic effective amount.

Claims 55-63 (Cancelled).